Two River Group

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

IconOVir Bio is a preclinical-stage biotechnology company focused on developing oncolytic virus therapies for cancer treatment. Its proprietary platform aims to overcome limitations of earlier generations, enabling personalized cancer care.

Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Willow is stylish affordable disposable underwear that offers comfort, confidence, and leak-free protection, delivered discreetly to your door at a fraction of the price. Current options on the market are either expensive or bulky and generally lacking in style — plus, you have to purchase them at the store. Willow’s product is the thinnest and most absorbent on the market, and has better odor control than other products. It’s extremely "breathable” and wicks liquid away from skin, just like sportswear. Best of all, Willow’s stylish products cost less than others because they are sold directly to the consumer, with no mark up by stores.

Hubble Contacts provides contact lenses and eyewear at affordable prices with a focus on simplicity and convenience. Originated to make eye care accessible to as many people as possible, it has evolved to include high-quality eyeglasses and sunglasses in its product lineup. The company emphasizes an easy, hassle-free shopping experience and strong customer service to reduce the typical friction of reordering lenses and selecting frames. Guided by a mission to improve accessibility and affordability in eye care, Hubble Contacts seeks to offer reliable products and responsive support through a dedicated team.

Allogene Therapeutics is a clinical-stage biotech company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. The company builds a pipeline of off-the-shelf donor-derived CAR-T products using gene-editing and proprietary cell-manufacturing technologies to enable broader patient eligibility and scalable production. Its programs include UCART19 for relapsed or refractory acute lymphoblastic leukemia and other allogeneic CAR-T candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is primarily generated from collaborations and licensing agreements.

Founded in 2016, Andie is a New York-based online retailer specializing in women's swimwear. It offers a range of swimsuits, including one-piece and two-piece styles, along with accessories and gift cards. The company operates as a direct-to-consumer brand, providing high-design, luxurious swimwear at accessible prices.

Hubble Contacts provides contact lenses and eyewear at affordable prices with a focus on simplicity and convenience. Originated to make eye care accessible to as many people as possible, it has evolved to include high-quality eyeglasses and sunglasses in its product lineup. The company emphasizes an easy, hassle-free shopping experience and strong customer service to reduce the typical friction of reordering lenses and selecting frames. Guided by a mission to improve accessibility and affordability in eye care, Hubble Contacts seeks to offer reliable products and responsive support through a dedicated team.

Hubble Contacts provides contact lenses and eyewear at affordable prices with a focus on simplicity and convenience. Originated to make eye care accessible to as many people as possible, it has evolved to include high-quality eyeglasses and sunglasses in its product lineup. The company emphasizes an easy, hassle-free shopping experience and strong customer service to reduce the typical friction of reordering lenses and selecting frames. Guided by a mission to improve accessibility and affordability in eye care, Hubble Contacts seeks to offer reliable products and responsive support through a dedicated team.

Hubble Contacts provides contact lenses and eyewear at affordable prices with a focus on simplicity and convenience. Originated to make eye care accessible to as many people as possible, it has evolved to include high-quality eyeglasses and sunglasses in its product lineup. The company emphasizes an easy, hassle-free shopping experience and strong customer service to reduce the typical friction of reordering lenses and selecting frames. Guided by a mission to improve accessibility and affordability in eye care, Hubble Contacts seeks to offer reliable products and responsive support through a dedicated team.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, founded in 2015. The company specializes in developing innovative cell-based therapies aimed at treating cancer and other severe diseases. By harnessing the potential of the body's immune system, Cell Design Labs creates advanced therapies that are designed to target and eliminate malignant cells with high precision and safety. Its focus includes developing disruptive T cell receptor therapies that modify immune cells to recognize and destroy cancerous threats effectively. As a subsidiary of Gilead Sciences, Cell Design Labs is positioned to contribute significantly to the field of cancer treatment through its pioneering research and development efforts.

Hubble Contacts provides contact lenses and eyewear at affordable prices with a focus on simplicity and convenience. Originated to make eye care accessible to as many people as possible, it has evolved to include high-quality eyeglasses and sunglasses in its product lineup. The company emphasizes an easy, hassle-free shopping experience and strong customer service to reduce the typical friction of reordering lenses and selecting frames. Guided by a mission to improve accessibility and affordability in eye care, Hubble Contacts seeks to offer reliable products and responsive support through a dedicated team.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, focused on developing innovative therapies for specialty cancers and urologic diseases. The company is dedicated to transforming the standard of care in uro-oncology through its diverse pipeline of product candidates. Its lead products, including UGN-101 and UGN-102, aim to ablate tumors non-surgically and address various forms of non-muscle invasive urothelial cancer, such as low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. UroGen is also advancing UGN-201, an immunotherapy candidate targeting high-grade non-muscle invasive bladder cancer. Furthermore, the company's proprietary RTGel technology enhances drug delivery by enabling sustained release, improving therapeutic efficacy. UroGen has established licensing agreements with Allergan Pharmaceuticals for the development of RTGel-based products and with Agenus Inc. to commercialize treatments for urinary tract cancers. Founded in 2004, UroGen Pharma continues to innovate in the field of urology and oncology.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.